Pharmacokinetics of Antibiotics against Gram-Negative Infections in Continuous Ambulatory Peritoneal Dialysis Patients

Lameire N. , Ringoir S. Pharmacokinetic aspects of drug transport in continuous ambulatory peritoneal dialysis. In: Horl W.H. , Schollmeyer P.J. , eds. New perspectives in hemodialysis, peritoneal dialysis, arteriovenous hemofiltration and plasmapheresis. Plenum Press New York 1989: 105–16.

Janknegt R. , Koks C.H.W. Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: A literature review. Pharm Weekbl 1984; 6: 229–36.

Paton T.W. , Cornish W.R. , Manuel M.A. Drug therapy in patients undergoing peritoneal dialysis -clinical pharmacokinetic considerations. Clin Pharmacokinet 1985; 10: 404–26.

Keller E. , Reetze P. , Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis -clinical pharmacokinetic considerations. Clin Pharmacokinet 1990; 18: 104–17.

Koup J.R. , Keller E. , Neumann H. Ceftriaxone pharmacokinetics during peritoneal dialysis. Eur J Clin Pharmacol 1986; 30: 303–7.

Keller E. Peritoneal kinetics of different drugs. Clin NephroI 1988; 30: 824–8.

Gross M.L. , Somani P. , Ribner B.S. Ceftizoxim elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983; 34: 673–80.

Dahl K. , Walstad R.A. , Wideroe T.E. The effect of peritonitis on the trans peritoneal transport of cefuroxime in patients on CAPD treatment. Nephrol Dial Transplant 1990; 5: 275–81.

Albin H.C. , Demotes-Mainard F.M. , Bouchet J.L. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic peritoneal dialysis. Clin Pharmacol Ther 1985; 38: 285–9.

Alexander D. , Gamberto J. , Barriere S. Cefotaxime pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacal Ther 1984; 35: 225–8.

Brouard R. , Tozer T.N. , Meedjan H. Transperitoneal movement and pharmacokinetics of cefotiam and cefsulodin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1988; 30: 197–206.

Favre H. , Probst P. Phannacokinetics of ceftriaxone after intravenous administration to CAPD patients with and without peritonitis. In: Sabbour , ed. Chemioterapia. II sedicessimo, firenze 1987; 6(Suppl 2): 273–4.

Ti T.Y. , Fortin L. , Kreeft J.H. Kinetic disposition of intravenous ceftriaxone in nonnal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984; 25: 83–7.

Hodler J.E. , Gelazzi R.L. , Frey B. Phannacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: Clinical and pathophysiological implications. Eur J Clin Pharmacol 1984; 26: 609–12.

Keller E. , Jansen A. , Pelz K. Intraperitoneal and intravenous cefoperasone kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1984; 35: 208–13.

Johnson C.A. , Zimmennan S.W. , Reitberg D.P. Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1988; 32: 51–6.

Comstock T.J. , Straughn A.B. , Kraus A.P. Ceftazidime phannacokinetics during continuous ambulatory peritoneal dialysis (CAPD) and intermittent peritoneal dialysis (IPD). Drug Intell ClinPharm 1983; 17: 451–3.

Mendes P. , Lameire N. , Rosenkranz E. Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis. J Antimicrob Agents Chemother 1990; 26: S89–93.

Barbhaiya R.H. , Knupp C.A. , Pfeffer M. Pharmacokinetics of cefopime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1992; 36: 1387–91.

Albin H. , Ragnaud J.M. , Demot-Mainard F. Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1986; 30: 299–302.

Singlas E. , Eoutron H.F. , Merdjan H. Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacal Ther 1983; 34: 403–7.

Janicke D.M. , Morse G.D. , Apicella M.A. Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacal Ther 1986; 40: 209–18.

Smeltzer E.D. , Schwartzman M.S. , Eertino J.S. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis. J Antimicrob Agents Chemother 1988; 32: 236–40.

Pancorbo S. , Comty C. Phannacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. J Antimicrob Agents Chemother 1981; 19: 605–7.

Walshe J.J. , Morse G.D. , Janicke D.M. Crossover phannacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin. J Infect Dis 1986; 153: 196–9.

Pat ton T.W. , Manuel M.A. , Walka S.E. Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1982; 2: 179–81.

Ryckelynck J Ph , Debruyne D. , Hurault De Ligny E. Pharmacocinétique de la piperacilline en dialyse péritoneale continue ambulatoire. Path Biol 1988; 36: 507–10.

Eoelaert J. , Daneels R. , Schurgers M. The pharmacokinetics of temocillin in patients with nonnal and impaired renal function. J Antimicrob Chemother 1983; 11: 349–56.

Elackwell B.G. , Leggett J.E. , Johnson C.A. Ampicillin and sulbactam phannacokinetics and phannacodynamics in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10: 221–6.

Somani P. , Freimer E.H. , Gross H.L. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1988; 32: 530–4.

Gerig S.J. , Eolton N.D. , Swabb E.A. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int 1984; 26: 308–18.

Lameire N. , Bogaert M. , Eelpaire F. Peritoneal pharmacokinetics and pharmacological manipulations of peritoneal transport. In: Gokal R. , ed. Continuous ambulatory peritoneal dialysis. Edinburgh: Churchill Livingstone, 1986: 56–93.

Rogge M.C. , Johnson C.A. , Zimmennan S.W. Vancomycin disposition during continuous ambulatory peritoneal dialysis: A pharmacokinetic analysis of peritoneal transport. Antimicrob Agents Chemother 1985; 27: 578–83.

Petersen J. , Stewart R.D.M. , Cat to G.R.D. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Nephron 1985; 40: 79–82.

Arvidsson A. , Alvan G. , Tranaeus A. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1985; 28: 333–7.

Tourkantonis A. , Nicolaidis P. Phannacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother 1983; 12(Suppl A): 263–7.

Nikolaidis P. , Dombros N. , Alexion P. Pharmacokinetics of aztreonam administered IP in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Bull 1989; 9: 57–9.

Janknegt R. , Koks C.H.W. , Nube M.J. Stabilityofantibiotics in CAPD fluid. Perit Dial Bull 1985; 5: 78–9.

De Paepe M. , Lameire N. , Belpaire F. Peritoneal phannacokinetics of gentamicin in man. Clin Nephrol 1983; 19: 107–9.

Chong T.K. , Piraino B. , Eernardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis. Perit Dial Bull 1991; 11: 152–5.

Ponce S.P. , Earata J.D. , Santos R. Interference of heparin with peritoneal solute transport. Nephron 1985; 39: 47–9.

Rubin J. Tobramycin absorption from the peritoneal cavity. Perit Dial Bull 1990; 10: 295–7.

Rubin J. , Deraps G.D. , Walsh D. Protein losses and tobramycin absorption in peritonitis treated by hourly peritoneal dialysis. Am J Kidney Dis 1986; 8: 124–7.

Nikolaidis P. , Vas S. , Lawson V. Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit Dial Bull 1991; 11: 156–61.

Dratwa M. , Glupczynski Y. , Lameire N. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1991; 13: S645–7.